
PatentNov 19, 2026, 09:30 AM
Cingulate Inc. Secures Patent for Precision Timed Release Buspirone Tablet
AI Summary
Cingulate Inc. announced the USPTO has issued U.S. Patent No. 12,797,335, titled "Trimodal, Precision-Timed Release Tablet." This patent covers a buspirone tablet formulation using Cingulate's proprietary PTR™ technology, designed for three timed releases from a single tablet. The company plans to advance its lead ADHD treatment candidate, CTx-1301, toward NDA resubmission in late 2026 or early 2027, and anticipates initiating development of CTx-2103 for anxiety disorders post-approval of CTx-1301. This patent strengthens Cingulate's intellectual property portfolio and demonstrates the versatility of its PTR™ platform.
Key Highlights
- USPTO issues U.S. Patent No. 12,797,335 for a trimodal, precision-timed release buspirone tablet.
- Patent covers Cingulate's proprietary Precision Timed Release™ (PTR™) technology for timed medication release.
- Formulation supports development of CTx-2103 for anxiety disorders, demonstrating platform versatility beyond ADHD.
- Cingulate remains focused on advancing CTx-1301 (ADHD candidate) toward NDA resubmission in H2 2027.
- Company anticipates initiating development of CTx-2103 after CTx-1301 approval.
- The newly issued patent strengthens Cingulate's intellectual property portfolio.
Price Impact
More from CING